，/PRNewswire/ -- 男性一直在期待除了避孕套和输精管切除术之外的新男性避孕选择。非激素方法在男性关注中处于前沿，包括 长效、可逆 的选择和 临时、按需解决方案。NEXT Life Sciences，一家生殖和性健康领域的领导者，正在通过两种满足这些需求的男性避孕选择，彻底改变避孕类别，这两种选择均处于积极的临床试验中。
继续阅读
<img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/>
两种男性避孕选择进入第二阶段临床试验
在 2025 年，NEXT Life Sciences 的旗舰产品 Plan A™，一种长效、非激素、可按需逆转的选择，在澳大利亚和加拿大的早期试验中证明其输送装置 100% 成功。2025 年 10 月，它进入了第二阶段临床试验，完整的 Plan A™避孕系统也随之进入试验。
&#34;我们很高兴现在有两种男性避孕药物进入临床试验，并且初步结果令人鼓舞。随着更多生殖和性健康产品的开发，NEXT Life Sciences 正在成为非激素、可逆按需避孕选择的领导者，&#34;NEXT Life Sciences 首席执行官 Darlene Walley 博士 表示。&#34;由于超过 20% 的女性无法耐受激素避孕，某些情况下会导致严重后果，因此夫妻双方需要多种家庭计划选择，尤其是无激素的选择。&#34;
NEXT Life Sciences 还很高兴地推出了一种男性避孕解决方案，针对有兴趣按需解决方案的男性和夫妻，NLS-133，一种非激素男性避孕药，旨在提供 24 小时的保护，可作为按需或每日药物使用。NLS-133 已开始第二阶段临床试验，参与者在服用非激素避孕药后，其精液水平正在被评估，以进一步证明 NLS-133 的有效性。
Plan A™ 和 NLS-133 共同使 NEXT Life Sciences 成为 男性避孕综合平台的首要领导者，回应了越来越多的证据表明男性和夫妻正在寻求额外的安全有效的选择，以决定何时以及是否要生育。
&#34;作为男性避孕的领导者，NEXT Life Sciences 正在推出令人兴奋的新机会，让男性及其伴侣拥有比避孕套和输精管切除术更多的选择，&#34;NEXT Life Sciences 首席技术官 Bob Dudley 博士 解释道。&#34;我们的变革性生殖和性健康产品将彻底改变这一投资和创新极少的医疗领域，最终为这一未满足的需求带来解决方案。&#34;
目前，全球一半的怀孕仍然是意外的，这突显了可用选择与人们实际规划生活之间的持续差距。同时，避孕的负担几乎完全落在女性身上。最近的数据表明，50% 的女性经历的避孕副作用比预期更严重，进一步推动了对更好替代方案的需求。
对共享避孕责任的期望也在发生变化。发表在《Andrology》上的研究表明，7 成男性愿意尝试新的男性避孕方法，这表明他们准备更广泛地参与家庭计划。然而，男性的选择仍然仅限于避孕套或输精管切除术，导致需求未得到满足。
这种脱节指向一个简单的结论：避孕并非一刀切。随着 Plan A™ 和 NLS-133 的推进，NEXT Life Sciences 正在直接回应长期未满足的需求，扩大男性和夫妻在全球的避孕选择。
在美国，有超过 1700 万男性积极寻求新的避孕选择，夫妻们要求在家庭计划中承担更多的共同责任，这一领域的创新需求从未如此迫切。
为了支持未来的持续临床开发和扩展，NEXT Life Sciences 计划在 2026 年进行 A 轮融资，此前的种子轮融资已超额认购。
欲了解更多信息，请访问 https://www.nextlifesciences.org/ 或 https://www.planaformen.com/。
媒体联系人：
[email protected]
免责声明
所有前瞻性声明并不保证未来的表现，不应过度依赖这些声明。本文件中的声明尚未经过美国食品药品监督管理局的评估。Plan A™和 NLS-133 目前尚未获得 FDA 的商业分销批准。
来源：NEXT Life Sciences, Inc.
<img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjE5Jk5ld3NJdGVtSWQ9TEE5MTg1MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMTkxNTIyUFJfTkVXU19VU1BSX19fX19MQTkxODUx?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjE5Jk5ld3NJdGVtSWQ9TEE5MTg1MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMTkxNTIyUFJfTkVXU19VU1BSX19fX19MQTkxODUx"/>

OLSI

TLSA

生物科技 ETF - VanEck Vectors

NEXT Life Sciences 已将两种男性避孕选择，Plan A™ 和 NLS-133，推进至第二阶段临床试验。Plan A™ 是一种长效、非激素、可按需可逆的避孕方法，而 NLS-133 是一种提供 24 小时保护的非激素药丸。这两种选择旨在满足男性避孕的未满足需求，因为目前的选择仅限于安全套和输精管结扎。该公司计划在 2026 年进行 A 轮融资，以支持进一步的发展。随着对新避孕方法的需求显著增加，NEXT Life Sciences 在这一创新领域中处于领先地位

, /PRNewswire/ -- Men have long been waiting for new male contraceptive options outside of just condoms and vasectomy. Non-hormonal methods at the forefront of male interest have been long-acting, reversible options and temporary, on-demand solutions. NEXT Life Sciences, a leader in reproductive and sexual health companies, is revolutionizing the contraceptive category with two male birth control options that meet these needs, both in active clinical trials.
<div class="lb-trans">，/PRNewswire/ -- 男性一直在期待除了避孕套和输精管切除术之外的新男性避孕选择。非激素方法在男性关注中处于前沿，包括 长效、可逆 的选择和 临时、按需解决方案。NEXT Life Sciences，一家生殖和性健康领域的领导者，正在通过两种满足这些需求的男性避孕选择，彻底改变避孕类别，这两种选择均处于积极的临床试验中。
</div>Continue Reading
<div class="lb-trans">继续阅读
</div><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/>
Two Male Birth Control Options Advance Into Phase II Clinical Trials
<div class="lb-trans">两种男性避孕选择进入第二阶段临床试验
</div>In 2025, NEXT Life Sciences' flagship product, Plan A™, a long-acting, non-hormonal, and reversible-on-demand option, proved its delivery device 100% successful in early trials in Australia and Canada. In October 2025, it entered Phase II clinical trials with the full Plan A™ contraceptive system.
<div class="lb-trans">在 2025 年，NEXT Life Sciences 的旗舰产品 Plan A™，一种长效、非激素、可按需逆转的选择，在澳大利亚和加拿大的早期试验中证明其输送装置 100% 成功。2025 年 10 月，它进入了第二阶段临床试验，完整的 Plan A™避孕系统也随之进入试验。
</div>&#34;We are thrilled to have two male contraceptives now in clinical trials with promising preliminary results. With a broader pipeline of reproductive and sexual health products in development, NEXT Life Sciences is stepping forward as the leader in non-hormonal, reversible-on-demand contraceptive options,&#34; said Darlene Walley, PhD, Chief Executive Officer of NEXT Life Sciences. &#34;Since over 20 percent of women cannot tolerate hormonal birth control, in some cases with severe consequences, it's important that couples have multiple family planning options and particularly ones without hormones.&#34;
<div class="lb-trans">&#34;我们很高兴现在有两种男性避孕药物进入临床试验，并且初步结果令人鼓舞。随着更多生殖和性健康产品的开发，NEXT Life Sciences 正在成为非激素、可逆按需避孕选择的领导者，&#34;NEXT Life Sciences 首席执行官 Darlene Walley 博士 表示。&#34;由于超过 20% 的女性无法耐受激素避孕，某些情况下会导致严重后果，因此夫妻双方需要多种家庭计划选择，尤其是无激素的选择。&#34;
</div>NEXT Life Sciences is also pleased to reveal a male contraceptive solution for men and couples interested in on-demand solutions with NLS-133, a non-hormonal male contraceptive pill, designed to provide 24 hours of protection and for use as either an on-demand or daily pill. NLS-133 has begun a Phase II clinical trial where participants' semen levels are being evaluated after taking the non-hormonal contraceptive pill to further demonstrate the effectiveness of NLS-133.
<div class="lb-trans">NEXT Life Sciences 还很高兴地推出了一种男性避孕解决方案，针对有兴趣按需解决方案的男性和夫妻，NLS-133，一种非激素男性避孕药，旨在提供 24 小时的保护，可作为按需或每日药物使用。NLS-133 已开始第二阶段临床试验，参与者在服用非激素避孕药后，其精液水平正在被评估，以进一步证明 NLS-133 的有效性。
</div>Together, Plan A™ and NLS-133 position NEXT Life Sciences as the foremost leader in comprehensive platforms for male contraception, responding to mounting evidence that men and couples are seeking additional safe and effective options to utilize when choosing when and if to have a child.
<div class="lb-trans">Plan A™ 和 NLS-133 共同使 NEXT Life Sciences 成为 男性避孕综合平台的首要领导者，回应了越来越多的证据表明男性和夫妻正在寻求额外的安全有效的选择，以决定何时以及是否要生育。
</div>&#34;As a leader in male contraceptives, NEXT Life Sciences is bringing exciting new opportunities to market so men and their partners can have more choices than just condoms and vasectomies,&#34; explained Bob Dudley, PhD, Chief Technology Officer at NEXT Life Sciences. &#34;Our transformative reproductive and sexual health products will revolutionize an area of healthcare that has had very little investment and innovation, finally bringing solutions to this unmet need.&#34;
<div class="lb-trans">&#34;作为男性避孕的领导者，NEXT Life Sciences 正在推出令人兴奋的新机会，让男性及其伴侣拥有比避孕套和输精管切除术更多的选择，&#34;NEXT Life Sciences 首席技术官 Bob Dudley 博士 解释道。&#34;我们的变革性生殖和性健康产品将彻底改变这一投资和创新极少的医疗领域，最终为这一未满足的需求带来解决方案。&#34;
</div>Currently, half of pregnancies worldwide remain unplanned, highlighting a persistent gap between available options and how people actually plan their lives. At the same time, the burden of contraception continues to fall almost entirely on women. Recent data shows that 50% of women experience side effects from birth control that are more severe than expected, further fueling this demand for better alternatives.
<div class="lb-trans">目前，全球一半的怀孕仍然是意外的，这突显了可用选择与人们实际规划生活之间的持续差距。同时，避孕的负担几乎完全落在女性身上。最近的数据表明，50% 的女性经历的避孕副作用比预期更严重，进一步推动了对更好替代方案的需求。
</div>Expectations around shared contraceptive responsibility are also shifting. Research published in Andrology indicates that 7 in 10 men are willing to try new male contraceptive methods, signaling readiness for broader participation in family planning. Yet male options remain limited to condoms or vasectomy, leaving demand unmet.
<div class="lb-trans">对共享避孕责任的期望也在发生变化。发表在《Andrology》上的研究表明，7 成男性愿意尝试新的男性避孕方法，这表明他们准备更广泛地参与家庭计划。然而，男性的选择仍然仅限于避孕套或输精管切除术，导致需求未得到满足。
</div>This disconnect points to a simple conclusion: contraception is not one size fits all. Advancing Plan A™ alongside NLS-133, NEXT Life Sciences is responding directly to a long-unmet need, expanding contraceptive choice for men and couples worldwide.
<div class="lb-trans">这种脱节指向一个简单的结论：避孕并非一刀切。随着 Plan A™ 和 NLS-133 的推进，NEXT Life Sciences 正在直接回应长期未满足的需求，扩大男性和夫妻在全球的避孕选择。
</div>With over 17 million American men actively seeking new contraceptive options and couples asking for more shared responsibility in family planning, the need for innovation in this space has never been greater.
<div class="lb-trans">在美国，有超过 1700 万男性积极寻求新的避孕选择，夫妻们要求在家庭计划中承担更多的共同责任，这一领域的创新需求从未如此迫切。
</div>To support future continued clinical development and expansion, NEXT Life Sciences is planning a Series A round in 2026, following an oversubscribed Seed round.
<div class="lb-trans">为了支持未来的持续临床开发和扩展，NEXT Life Sciences 计划在 2026 年进行 A 轮融资，此前的种子轮融资已超额认购。
</div>For more information, visit https://www.nextlifesciences.org/ or https://www.planaformen.com/.
<div class="lb-trans">欲了解更多信息，请访问 https://www.nextlifesciences.org/ 或 https://www.planaformen.com/。
</div>Media Contact:
<div class="lb-trans">媒体联系人：
</div>[email protected]
<div class="lb-trans">[email protected]
</div>Disclaimer
<div class="lb-trans">免责声明
</div>All forward-looking statements are not guarantees of future performance, and undue reliance should not be placed on them. Statements within this document have not been evaluated by the U.S. Food and Drug Administration. Plan A™ and NLS-133 are currently not approved by the FDA for commercial distribution.
<div class="lb-trans">所有前瞻性声明并不保证未来的表现，不应过度依赖这些声明。本文件中的声明尚未经过美国食品药品监督管理局的评估。Plan A™和 NLS-133 目前尚未获得 FDA 的商业分销批准。
</div>SOURCE NEXT Life Sciences, Inc.
<div class="lb-trans">来源：NEXT Life Sciences, Inc.
</div><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMjE5Jk5ld3NJdGVtSWQ9TEE5MTg1MSZUcmFuc21pc3Npb25fSWQ9MjAyNjAyMTkxNTIyUFJfTkVXU19VU1BSX19fX19MQTkxODUx" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=LA91851&amp;Transmission_Id=202602191522PR_NEWS_USPR_____LA91851&amp;DateId=20260219"/>

15:22 ET 两种男性避孕方案进入 II 期临床试验